Cefotaxime treatment of Haemophilus ducreyi infection in Kenya.
View/ Open
Date
1984-12Author
Plummer, FA
Maggwa, N
D'Costa, LJ
Nsanze, H
Karasira, P
Maclean, IW
Ronald, AR
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
The authors conducted a double-blind randomized clinical trial comparing single-dose cefotaxime (1 g im) plus daily placebo injections with cefotaxime (1 g im on each of three days). Each regimen was given with probenicid (1 g orally) for the treatment of chancroid. Twenty Haemophilus ducreyi culture-positive men received the single-dose cefotaxime regimen; in eight patients ulcers or buboes failed to respond to therapy. Nineteen H. ducreyi culture-positive men received cefotaxime on each of three days; H. ducreyi was eradicated from all patients, but one had a continuing ulcer and another had a bubo that failed to respond. Thus cefotaxime (1 g im daily for three days) plus probenicid (1 g orally) is effective therapy for chancroid. The lack of efficacy for chancroid of the single-dose cefotaxime regimen is surprising, given the remarkable susceptibility of H. ducreyi to cefotaxime; presumably the half-life of cefotaxime is too short for predictable eradication of H. ducreyi from the ulcer with a single-dose regimen.
URI
http://www.ncbi.nlm.nih.gov/pubmed/6098034http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/31234
Citation
Sex Transm Dis. 1984 Oct-Dec;11(4):304-7.Publisher
University of Nairobi, Department of Medicine
Collections
- Faculty of Health Sciences (FHS) [10378]